HSBC Holdings’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-30,000
Closed -$5.52M 2910
2025
Q4
$5.52M Buy
+30,000
New +$5.26M ﹤0.01% 1165
2020
Q1
Sell
-4,550
Closed -$453K 2699
2019
Q4
$453K Hold
4,550
﹤0.01% 2277
2019
Q3
$406K Buy
+4,550
New +$395K ﹤0.01% 2442
2018
Q3
Sell
-60,000
Closed -$4.21M 2537
2018
Q2
$4.21M Buy
+60,000
New +$4.32M 0.01% 1194
2013
Q3
Sell
-26,851
Closed -$1.27M 1651
2013
Q2
$1.27M Buy
+26,851
New +$1.37M ﹤0.01% 1036

Other funds holding AZN

HSBC Holdings's AZN Position: Q2 2026 in Review

HSBC Holdings reduced its AstraZeneca (AZN) stake by 12% in Q2 2026, selling an estimated $141K and leaving 5,545 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1918.

HSBC Holdings first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. The position peaked at $494M in Q4 2021. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • HSBC Holdings held 5,545 shares of AstraZeneca worth $1.05M as of Q2 2026.
  • HSBC Holdings sold 752 AstraZeneca shares in Q2 2026, an estimated $141K.
  • AstraZeneca made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #1918 holding.
  • HSBC Holdings first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
  • HSBC Holdings's AstraZeneca position peaked at $494M in Q4 2021.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.